{"id":"NCT00814320","sponsor":"Baxalta now part of Shire","briefTitle":"Gammagard Liquid and rHuPH20 in PID","officialTitle":"Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-18","primaryCompletion":"2010-11-11","completion":"2010-11-11","firstPosted":"2008-12-24","resultsPosted":"2015-12-03","lastUpdate":"2021-05-19"},"enrollment":89,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Diseases (PID)"],"interventions":[{"type":"BIOLOGICAL","name":"Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)","otherNames":["HYQVIA"]},{"type":"BIOLOGICAL","name":"Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to develop a subcutaneous treatment option for participants with Primary Immunodeficiency Diseases (PID) that allows an administration of Immune Globulin Intravenous (Human), 10% at the same frequency as IV administration.","primaryOutcome":{"measure":"Validated Acute Serious Bacterial Infection (VASBI) Rate","timeFrame":"Throughout the study period (17 months)","effectByArm":[{"arm":"Full Analysis Data Set (FADS)","deltaMin":0.025,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":19},"locations":{"siteCount":14,"countries":["United States","Canada"]},"refs":{"pmids":["27220317","22846381","34931880"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":87},"commonTop":["HEADACHE","SINUSITIS","UPPER RESPIRATORY TRACT INFECTION","INFUSION SITE PAIN","NAUSEA"]}}